Melanotan II (MT-II) is an injectable peptide sold for a suntan without much sun. It is genuinely effective at darkening skin, which is why it persists as a grey-market product despite being unlicensed. It also has a second, often unadvertised effect on sexual arousal, and a set of side effects and safety questions that deserve to be stated as plainly as the tanning claim. This guide covers what it is, what it does, and what the honest risk picture looks like.
MT-II is not an approved medicine anywhere for cosmetic tanning. What is sold online is a research-grade peptide of uncertain purity, self-injected without medical oversight.
What it is and how it works
Melanotan II is a synthetic, cyclic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It is a non-selective agonist at the melanocortin receptors:
- At MC1R on melanocytes, it stimulates production of eumelanin — the darker pigment — producing tanning that can develop with less UV exposure than normal.
- At MC4R in the brain, it influences appetite and sexual arousal, which is why users report reduced appetite and spontaneous erections or increased libido.
That MC4R activity is not a side story: the erectile effect seen in early melanocortin research led directly to the development of bremelanotide (PT-141), an MC4R-focused peptide that is FDA-approved for hypoactive sexual desire disorder in premenopausal women. PT-141 is the regulated descendant of this same pharmacology, developed specifically for arousal rather than tanning.
It is worth distinguishing the two "Melanotans." Melanotan I (afamelanotide) is an approved slow-release implant (Scenesse) used under supervision for a rare light-sensitivity disorder. Melanotan II — the injectable sold for cosmetic tanning — is the unregulated one and the subject of this guide.
What people use it for
- Tanning with less UV. Small early-phase human studies did confirm MT-II produces skin darkening, and users typically pair it with some UV exposure to trigger and maintain the tan.
- Libido and erections. The MC4R effect is real enough that some users take it primarily for that, and it is the mechanism validated (in a refined form) by the approval of PT-141.
- Appetite suppression. Often reported as a secondary effect rather than a goal.
The real risks
This is where honesty matters most, because the tanning benefit is easy to see and the risks are easy to downplay:
- Nausea and flushing. Very commonly reported, especially early in use, along with facial flushing and, for some, spontaneous erections and yawning — classic melanocortin effects.
- Blood pressure and cardiovascular effects. Melanocortin agonism can affect blood pressure and heart rate; this is not a benign cosmetic with no systemic reach.
- Darkening and change of moles. MT-II darkens existing naevi (moles) and can prompt new pigmented lesions. Dermatologists have raised specific concern that it may darken, alter, or mask melanocytic lesions, complicating skin-cancer detection.
- Melanoma concern. There are published case reports of melanoma in MT-II users and of eruptive or changing moles. Whether the peptide causes melanoma or simply makes existing lesions harder to interpret is not settled, but either way the sensible position is heightened skin surveillance.
- Injection and product risk. As an unlicensed injectable, purity and sterility are not guaranteed, adding contamination and infection risk on top of the pharmacology.
Anyone using it should have a low threshold for a dermatology skin check, should watch existing moles for change in size, shape, or colour, and should understand that a darkening mole on MT-II is a reason to get examined, not to assume it is "just the tan."
Legal and regulatory status
Melanotan II is not approved as a medicine for tanning in the US, EU, UK, or Australia, and regulators including the FDA, MHRA, and TGA have warned against unlicensed melanotan products sold online and in some tanning venues. Selling it for human use is unlawful in many jurisdictions even where possession is not directly penalised.
Bottom line
Melanotan II works: it darkens skin through MC1R and drives arousal through MC4R, the latter being the pharmacology that produced the approved drug PT-141. But it is an unlicensed, self-injected peptide with a genuine side-effect load — nausea, flushing, blood-pressure effects — and a real dermatological red flag around darkening moles and melanoma detection. The tanning is visible; the risks are the part the marketing tends to omit. Anyone using it should treat moles as something to monitor closely and get checked, not ignore.